Fragment-based discovery of focal adhesion kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 19, 2013, Pages 5401-5409

  Grädler, Ulrich ^a   Bomke, Jörg ^a   Musil, Djordje ^a   Dresing, Verena ^a   Lehmann, Martin ^a   Hölzemann, Günter ^a   Greiner, Hartmut ^a   Esdar, Christina ^a   Krier, Mireille ^a   Heinrich, Timo ^a  

^a Merck Serono GmbH   (Germany)

Author keywords

DFG out; Focal adhesion kinase; Fragment screening; Surface plasmon resonance; X ray structure

Indexed keywords

FOCAL ADHESION KINASE INHIBITOR;

ANIMAL CELL; AQUEOUS SOLUTION; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME CONFORMATION; FOLLOW UP; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; STEADY STATE; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

DFG-OUT; FOCAL ADHESION KINASE; FRAGMENT SCREENING; SURFACE PLASMON RESONANCE; X-RAY STRUCTURE;

CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; ENZYME INHIBITORS; FOCAL ADHESION PROTEIN-TYROSINE KINASES; INDOLES; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; SMALL MOLECULE LIBRARIES; SOLUBILITY; SULFONAMIDES; SURFACE PLASMON RESONANCE;

EID: 84883489372     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.07.050     Document Type: Article

References (35)

1. J.E. Hall, W. Fu, and M.D. Schaller Int. Rev. Cell Mol. Biol. 288 2011 185
2. X. Peng, and J.L. Guan Curr. Protein Pept. Sci. 12 2011 52
3. M.C. Bagley, T. Davis, M.C. Dix, C.S. Widdowson, and D. Kipling Org. Biomol. Chem. 4 2006 4158
4. D. Lietha, X. Cai, D.F. Ceccarelli, Y. Li, M.D. Schaller, and M.J. Eck Cell 129 2007 1177
5. W.G. Cance, J.E. Harris, M.V. Iacocca, E. Roche, X. Yang, J. Chang, S. Simkins, and L. Xu Clin. Cancer Res. 6 2000 2417
6. V.M. Golubovskaya, F.A. Kweh, and W.G. Cance Histol. Histopathol. 24 2009 503
7. G.W. McLean, N.O. Carragher, E. Avizienyte, J. Evans, V.G. Brunton, and M.C. Frame Nat. Rev. Cancer 5 2005 505
8. M. Hennig, A. Ruf, and W. Huber Top. Curr. Chem. 317 2012 115
9. C.A. Lepre Methods Enzymol. 493 2011 219
10. D.E. Scott, A.G. Coyne, S.A. Hudson, and C. Abell Biochemistry 51 2012 4990
11. W.G. Roberts, E. Ung, P. Whalen, B. Cooper, C. Hulford, C. Autry, D. Richter, E. Emerson, J. Lin, J. Kath, K. Coleman, L. Yao, L. Martinez-Alsina, M. Lorenzen, M. Berliner, M. Luzzio, N. Patel, E. Schmitt, S. LaGreca, J. Jani, M. Wessel, E. Marr, M. Griffor, and F. Vajdos Cancer Res. 2008 1935 68
12. G.W. Bemis, and M.A. Murcko J. Med. Chem. 39 1996 2887
13. A.L. Hopkins, C.R. Groom, and A. Alex Drug Discovery Today 9 2004 430
14. FAK protein crystallization has been performed as previously described Heinrich J. Med. Chem. 56 2013 1160
15. J. Zhang, P.L. Yang, and N.S. Gray Nat. Rev. Cancer 9 2009 28
16. G.E. de Kloe, D. Bailey, R. Leurs, and I.J. de Esch Drug Discovery Today 14 2009 630
17. C.W. Murray, M.L. Verdonk, and D.C. Rees Trends Pharmacol. Sci. 33 2012 224
18. The atomic coordinates and structure factors for the kinase domain of FAK in complex with 3, 6, 13 and 27 have been deposited in the Protein Data Bank (www.rcsb.org) under the accession codes 4K8 A, 4KAB, 4K9Y and 4KAO, respectively.
19. R.A. Norman, D. Toader, and A.D. Ferguson Trends Pharmacol. Sci. 33 2012 273
20. M. Iwatani, H. Iwata, A. Okabe, R.J. Skene, N. Tomita, Y. Hayashi, Y. Aramaki, D.J. Hosfield, A. Hori, A. Baba, and H. Miki Eur.J. Med. Chem. 61 2012 60
21. T. Heinrich, J. Seenisamy, L. Emmanuvel, S.S. Kulkarni, J. Bomke, F. Rohdich, H. Greiner, C. Esdar, M. Krier, U. Gradler, and D. Musil J.Med. Chem. 56 2013 1170
22. S. Han, A. Mistry, J.S. Chang, D. Cunningham, M. Griffor, P.C. Bonnette, H. Wang, B.A. Chrunyk, G.E. Aspnes, D.P. Walker, A.D. Brosius, and L. Buckbinder J. Biol. Chem. 284 2009 13193
23. H. Avraham, S.Y. Park, K. Schinkmann, and S. Avraham Cell. Signal. 12 2000 123
24. N. Moss, S. Breitfelder, R. Betageri, P.F. Cirillo, T. Fadra, E.R. Hickey, T. Kirrane, R.R. Kroe, J. Madwed, R.M. Nelson, C.A. Pargellis, K.C. Qian, J. Regan, A. Swinamer, and C. Torcellini Bioorg. Med. Chem. Lett. 17 2007 4242
25. B.M. Suijkerbuijk, I. Niculescu-Duvaz, C. Gaulon, H.P. Dijkstra, D. Niculescu-Duvaz, D. Menard, A. Zambon, A. Nourry, L. Davies, H.A. Manne, F. Friedlos, L.M. Ogilvie, D. Hedley, F. Lopes, N.P. Preece, J. Moreno-Farre, F.I. Raynaud, R. Kirk, S. Whittaker, R. Marais, and C.J. Springer J. Med. Chem. 53 2010 2741
26. H. Iwata, S. Imamura, A. Hori, M.S. Hixon, H. Kimura, and H. Miki Biochemistry 50 2011 738
27. R.A. Copeland, D.L. Pompliano, and T.D. Meek Nat. Rev. Drug Disc. 5 2006 730
28. H. Lu, and P.J. Tonge Curr. Opin. Chem. Biol. 14 2010 467
29. T.W. Johnson, K.R. Dress, and M. Edwards Bioorg. Med. Chem. Lett. 19 2009 5560
30. D.E. Clark Future Med. Chem. 3 2011 469
31. P. Ertl, B. Rohde, and P. Selzer J. Med. Chem. 43 2000 3714
32. Molecular Operating Environment (MOE), 2. 1.; Chemical Computing Group Inc., 1. S. St. W. S. #. M. Q. C. H. 2. 2, In: 2013.
33. Z.E. Barter, M.K. Bayliss, P.H. Beaune, A.R. Boobis, D.J. Carlile, R.J. Edwards, J.B. Houston, B.G. Lake, J.C. Lipscomb, O.R. Pelkonen, G.T. Tucker, and A. Rostami-Hodjegan Curr. Drug Metab. 8 2007 33
34. B. Davies, and T. Morris Pharm. Res. 10 1993 1093
35. T. Iwatsubo, H. Suzuki, and Y. Sugiyama J. Pharmacol. Exp. Ther. 283 1997 462